Lyell Immunopharma (NASDAQ:LYEL) COO Stephen Hill Sells 1,236 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) COO Stephen Hill sold 1,236 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the transaction, the chief operating officer owned 17,795 shares of the company’s stock, valued at approximately $416,225.05. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Lyell Immunopharma Trading Up 4.3%

NASDAQ LYEL traded up $1.04 on Thursday, reaching $25.38. 63,758 shares of the stock were exchanged, compared to its average volume of 86,064. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $45.00. The firm has a market capitalization of $539.07 million, a PE ratio of -1.10 and a beta of -0.14. The company’s 50-day simple moving average is $27.98 and its two-hundred day simple moving average is $19.64.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. Sell-side analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on LYEL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their target price for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $45.00.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently bought and sold shares of the stock. ARCH Venture Management LLC bought a new stake in shares of Lyell Immunopharma in the second quarter worth about $16,113,000. RBF Capital LLC bought a new position in Lyell Immunopharma during the second quarter valued at approximately $884,000. Vanguard Group Inc. grew its holdings in Lyell Immunopharma by 76.0% during the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after buying an additional 336,378 shares in the last quarter. Geode Capital Management LLC grew its holdings in Lyell Immunopharma by 25.1% during the 4th quarter. Geode Capital Management LLC now owns 162,997 shares of the company’s stock valued at $5,020,000 after buying an additional 32,740 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in Lyell Immunopharma in the 4th quarter worth approximately $2,976,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.